WHO: Indian strain of COVID-19 resistant to antibodies
Mutations of the Indian strain of COVID-19 indicate its high infectivity and resistance to antibodies in both those who have been ill and vaccinated, the World Health Organization reported.
New varieties of the virus have been discovered in India, including B.1.617. It is a variant with mutations E484Q and L452R that was first identified in India from samples collected on December 1, 2020.
According to preliminary research results, the L452R mutation may interfere with the effectiveness of certain monoclonal antibody treatments. E484Q can neutralize antibodies. Thus, the antibodies that have appeared in a person who has recovered from COVID-19 will not help in the fight against Indian mutations.
Moreover, the new strain is also thought to be highly virulent, which means it is more likely to infect and cause disease.
WHO experts have not yet figured out what influenced the virus mutations in India. One of the factors could be the holding of mass events that increased its spread, as well as the mitigation of antiquated measures in the country.




















Converse Bank shares its capital market expertise at the IV Conference Capital Markets Armenia
IDBank issued the 2nd and 3rd tranches of bonds of 2026
IDBank and Idram Continue Cooperation with the “ZARK” Educational Foundation
Idram&IDBank’s Special Offer at Dalma Garden Mall
The Power of One Dram Joins the Final Phase of the Symphonic Forest Project
The Badalyan Brothers Group of Companies Paid about 33.2 Billion AMD in Taxes and Duties to the Stat...
Ucom’s Level Up+ Packages with the Fastest Mobile Internet in Armenia
Ucom Issues Warning on New Wave of Phone Scams
Ucom’s Management Team Marks International Client’s Day with Subscribers
IDBank Launches Special Campaign for SWIFT Transfers